Poland· PL-100108059
Pamifos-30
A pamidronic acid product containing dinatrii pamidronas, registered in Poland by Vipharm S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pamidronic acid is registered in 8 of 19 countries.
Countries holding a registration under ATC M05BA03 (pamidronic acid), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Pamidronic acid · ATC M05BA03
8 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Dinatrii pamidronas
- Manufacturer
- Vipharm S.A.
- Country
- Poland (PL)
- ATC code
- M05BA03
- ATC class
- Pamidronic acid
- Defined daily dose
- 60 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
1 priced- gtin059099906616712 fiol. z prosz.po 30 mg + 2 amp.po 10 mlPLN 213.02
- gtin05909990937813
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
220 interactions on record for pamidronic acid.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pamidronic acid · interactions on record
220 records
- 12 severe
- 57 moderate
- 151 info
Most severe, free to view
- EtelcalcetideH05BX04severe
- SirolimusL01EG04severe
- SirolimusL04AA10severe
- TacrolimusL04AD02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pamidronic acid in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandArediaNovartis Finland Oy
- NetherlandsPamidronaatdinatrium Hospira 3 mg/ml, concentraat voor oplossing voor infusiePfizer B.V.
- SpainPAMIDRONATO HOSPIRA 3 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer S.L.
- FrancePAMIDRONATE DE SODIUM HOSPIRA 3 mg/mL, solution à diluer pour perfusionPFIZER HOLDING FRANCE
- Japanパミドロン酸二ナトリウム水和物沢井製薬
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- France · Pamidronate De Sodium Hospira
- Portugal · Pamidronato Hikma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b0705333-a93a-4a34-8152-78eb5a17ac43 GET /v1/drugs/b0705333-a93a-4a34-8152-78eb5a17ac43?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "30 mg",
"packaging": "05909990937813 ¦ Rp ¦ Skasowane ¦ 19280\n2 fiol. 30 mg proszku ¦ 2 amp. 10 ml rozp. (amp. PE)\n05909990661671 ¦ Rp ¦ 45590\n2 fiol. 30 mg proszku ¦ 2 amp. 10 ml rozp.",
"substance": "Dinatrii pamidronas 30 mg",
"common_name": "Dinatrii pamidronas",
"pl_product_id": "100108059",
"pozwolenie_nr": "09378",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about pamidronic acid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.